23andMe to launch GLP-1 telehealth offering, trims internal drug development team
Fierce Healthcare August 12, 2024
Consumer genetic testing company 23andMe sees an opportunity to get in on the weight loss boom.
The company, through its Lemonaid Health business, plans to launch a GLP-1 weight loss telehealth membership by the end of the month, it announced last week along with its fiscal first-quarter financial results.
The service will enable members to be prescribed and receive brand-name or compounded semaglutide medications, the company said.
“The addition of weight loss management for our customers fits directly within our strategy of delivering services to improve an individual’s health through preventive actions. We also continue to add features to our membership services as we focus on creating longitudinal value that can help our members remain focused on improving their health,”...